"It was a trade-off": San Francisco Catholic Archbishop Salvatore Cordileone says a security threat prompted him to move the worship service inside, possible violence due to a rumored protest and counter-protest next door at the Chinese Consulate.
"It was a trade-off": San Francisco Catholic Archbishop Salvatore Cordileone says a security threat prompted him to move the worship service inside, possible violence due to a rumored protest and counter-protest next door at the Chinese Consulate.
They admitted to submitting false gastric illness claims, which could have resulted in them getting a pay-out of tens of thousands of pounds.
The first 1.5-level enterprise port project of Haikou Jiangdong New Area has completely launched its investment attraction, according to Haikou Jiangdong New Area Development and Construction Co., Ltd. The investment attraction will focus on design, finance, technology and other industries, and corresponding preferential policies will be available for companies that have entered the port.
Top Players Covered in the Wearable Medical Devices Market Research Report are BD (New Jersey, United States), Ypsomed (Burgdorf, Switzerland), Fitbit, Inc. (San Francisco, United States), Apple Inc. (Cupertino, United States), Sonova (Stäfa, Switzerland), NeuroMetrix, Inc. (Waltham, United States), SAMSUNG (Suwon-si, South Korea), Omron Healthcare, Inc. (Kyoto, Japan), AiQ Smart Clothing (Taipei, Taiwan), Koninklijke Philips N.V. (Amsterdam, Netherlands) and other key market playersPune, India, March 01, 2021 (GLOBE NEWSWIRE) -- The global wearable medical devices market size is expected to showcase considerable growth by reaching USD 195.57 billion by 2027 while exhibiting an astounding CAGR of 26.4% between 2020 and 2027. This is ascribable to factors such as the increasing prevalence of chronic diseases and the growing awareness regarding fitness and wellness amongst the people that is driving the adoption of innovative wearable type of medical devices globally. Fortune Business Insights, in its latest report, titled, “Wearable Medical Devices Market Size, Share & COVID-19 Impact Analysis, By Product (Diagnostic & Patient Monitoring Wearable Medical devices, and Therapeutic Wearable Medical Devices); By Application (Remote Patient Monitoring & Home Healthcare, and Sports & Fitness); By Distribution Channel (Retail Pharmacies, Online Distribution and Hypermarkets & Others), and Regional Forecast, 2020-2027.”, observes that the market stood at USD 29.76 billion in 2019 and is likely to gain momentum in the forthcoming years. Request a Sample Copy of the Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/wearable-medical-devices-market-101070 Increasing Prevalence of Chronic Diseases to Accelerate Growth The sedentary lifestyle of people is likely to pave the way for the increasing prevalence of chronic diseases such as diabetes, heart disease, and others. According to the International Diabetes Federation, around 463 million adults aged between 20 to 79 suffer from diabetes. Additionally, by 2045, this number is expected to rise to about 700 million. The surging demand for innovative wearable type of medical devices owing to the growing awareness regarding the importance of fitness is expected to bode well for the global wearable medical devices market growth in the forthcoming years. COVID-19 Impact: Surge in Sales of Wearables Owing to Increasing Awareness Regarding Fitness The COVID-19 pandemic has led the people to look after their health regime more than before. The growing consumption of healthy diet and the increasing focus on maintaining proper sleep patterns is driving the sales of advanced wearable type of medical devices among people across the globe. This is likely to favor the market growth amid the widespread effects of the novel coronavirus. Additionally, the convenience of online shopping platforms has further led to the positive sales of the wearable devices globally. Click here to get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/wearable-medical-devices-market-101070 Diagnostic & Patient Monitoring Segment to Hold Dominant Position The diagnostic & patient monitoring segment, based on product, is expected to showcase substantial growth owing to the high disposable income of the young population that is propelling the sales of innovative wearable medical devices to monitor their overall health and fitness data. North America to Remain at Forefront; Key Players Launching Innovative Wearable Devices to Aid Growth Among all the regions, North America is expected to gain momentum and hold the highest position in the global market in the forthcoming years. This is attributable to the presence of established manufacturers that are introducing innovative devices to cater to the growing number of fitness enthusiasts in the region. On the other hand, Europe is expected to hold the second position in the market in the forthcoming years. This is ascribable to factors such as the increasing prevalence of chronic diseases among the elderly population that is likely to boost the adoption of innovative wearable medical devices in the region between 2020 and 2027. Quick Buy Wearable Medical Devices Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101070 List of the Companies Profiled in the Global Market: BD (New Jersey, United States)Ypsomed (Burgdorf, Switzerland)Fitbit, Inc. (San Francisco, United States)Apple Inc. (Cupertino, United States)Sonova (Stäfa, Switzerland)NeuroMetrix, Inc. (Waltham, United States)SAMSUNG (Suwon-si, South Korea)Omron Healthcare, Inc. (Kyoto, Japan)AiQ Smart Clothing (Taipei, Taiwan)Koninklijke Philips N.V. (Amsterdam, Netherlands)Other Prominent Player Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/wearable-medical-devices-market-101070 Table of Content: Introduction Research ScopeMarket SegmentationResearch MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket Opportunities Key Insights Recent Industry Developments- Partnerships, Mergers, and AcquisitionsKey Industry TrendsNew Product Launch by Key PlayersTechnological Advancements in Wearable Medical Devices MarketImpact of COVID-19 on the Market Global Wearable Medical Devices Market Analysis, Insights and Forecast, 2016-2027 Key Findings / SummaryMarket Analysis, Insights and Forecast – By Product Diagnostic & Patient Monitoring Wearable Medical Devices Activity Monitors/TrackersSmartwatchesSmart-clothingOthers (Biosensors, Blood Pressure Monitors, Glucose Monitoring Systems) Therapeutic Wearable Medical Devices Wearable DefibrillatorsDrug Delivery Devices (Injectors, Patches)Pain Management Devices (TENS, EMS)Hearing AidsOthers Market Analysis, Insights and Forecast – By Application Remote Patient Monitoring & Home HealthcareSports and Fitness Market Analysis, Insights and Forecast – By End User Retail PharmaciesOnline PharmaciesHypermarkets & Others Market Analysis, Insights and Forecast – By Region North AmericaEuropeAsia pacificRest of the World TOC Continued….! Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/wearable-medical-devices-market-101070 Have a Look at Related Reports: MicroRNA Market Size, Share & Covid-19 Impact Analysis, By Product (Instruments and Kits & Reagents) By Application (Isolation & Purification, Detection & Quantification, Disease Diagnostics, and Others) and By End User (Pharma & Biotech Companies, Academic & Research Institutes, Healthcare Facilities, and Others), Regional Forecast, 2020-2027 Foot Orthotic Insoles Market Size, Share & COVID-19 Impact Analysis, By Type (Prefabricated and Customized), By Application (Medical, Sports & Athletics, and Personal), By Material (Thermoplastics, Ethyl-vinyl Acetate (EVA), Foam, Composite Carbon Fiber, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Retail Stores, and Online Stores), and Regional Forecast, 2020-2027 Pet Insurance Market Share & Industry Analysis, By Policy Coverage Type (Accident & Illness, Accident Only, Others), By Animal Type (Dog, Cat, Others), By Provider (Public, Private) and Regional Forecast, 2019-2026 Vaccines Market Size, Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: firstname.lastname@example.orgFortune Business Insights™LinkedIn | Twitter | Blogs Press: https://www.fortunebusinessinsights.com/press-release/wearable-medical-devices-market-9217
Dublin, March 01, 2021 (GLOBE NEWSWIRE) -- The "Urgent Care Apps Market Share, Size, Trends, Industry Analysis Report, By Type; By Clinical Area; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global Urgent Care Apps market size is predicted to reach USD 9.81 billion by 2027Urgent Care Apps also known as 'immediate care' apps are designed to provide the instant virtual care to the patients and offer help to the healthcare providers in context with the serious medical conditions. The urgent care apps can be accessed 24/7 and helps to deliver the immediate course of action at emergency period. The urgent care apps also help to reduce the healthcare cost and provides virtual quality care like ER (Emergency Rooms).Recent developments in global market include the new app launches such as CURE ID, telehealth, virtual care apps, etc. The increasing awareness of addressing the emergency situations virtually leads to market growth.The prominent factors favoring the global market growth include increasing initiatives taken by the government and the legal authorities to address the diseases of the patients in the healthcare industry. For instance, in December 2019, the U.S. Food and drug Administration launched of an internet-based application i.e., CURE ID for healthcare professionals to treat patients with infectious diseases with novel uses of existing medicines through a smartphone, mobile device, and a website.The rising initiatives in the healthcare sector to provide an extensive care to the individuals leads to foster the growth of the global market. For instance, in March 2020, a healthcare startup for senior citizens, Arvi announced to launch an emergency app i.e., SOS which provides the function to press a button on the mobile app in case of emergency to receive medical support from the company.Market participants such as Medisafe, Forward Health, Allm, Johnson & Johnson, Pulsara, Hospify, TigerConnect, Vocera Communications, Twiage, PatientSafe Solutions, Imprivata, Voalte, Alayacare, Siilo, Pivot Design Group, and Argusoft are some of the key players operating in the global market.Players in the market are focusing on new launches of the app, increasing expansions, collaborations and partnerships to enhance their market and revenue share. For instance, in March 2020, the company Apple in collaboration with the CDC, the White House, and the (FEMA) Federal Emergency Management Agency has announced to launch an application and a website that helps an individual to do self-screening test for the COVID-19. The collaborations of the leading companies and the regulatory authorities formed to innovate an application based on the virtual screening of the coronavirus pandemic and care for the patients to lead them the healthier lives.Key Topics Covered: 1. Introduction2. Executive Summary3. Research Methodology4. Urgent Care Apps Market Insights4.1. Urgent Care Apps - Industry snapshot4.2. Urgent Care Apps Market Dynamics4.2.1. Drivers and Opportunities220.127.116.11. Increase in penetration of smartphones18.104.22.168. Busy lifestyle and lack in sufficient time for self-care4.2.2. Restraints and Challenges4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.5. Urgent Care Apps Market Industry trends5. Urgent Care Apps Market Assessment by Type5.1. Key Findings5.2. Introduction5.2.1. Global Urgent Care Apps Market, By Type, 2016-2027 (USD Million)5.3. In-hospital Communication & Collaboration Apps5.4. Pre-hospital Emergency Care & Triaging Apps5.5. Post-Hospital Apps5.5.1. Global Urgent Care Apps Market, by Post-Hospital Apps, by Region, 2016-2027 (USD Million)5.5.2. Rehabilitation Apps5.5.3. Care Provider Communication & Collaboration Apps5.5.4. Medication Management Apps6. Global Urgent Care Apps Market, by Clinical Area6.1. Key Findings6.2. Introduction6.2.1. Global Urgent Care Apps Market, By Clinical Area, 2016-2027 (USD Million)6.3. Stroke6.4. Cardiac Conditions6.5. Trauma6.6. Other Clinical Areas7. Urgent Care Apps Market Assessment by Geography7.1. Key findings7.2. Introduction7.2.1. Urgent Care Apps Market Assessment, By Geography, 2016-2027 (USD Million)8. Competitive Landscape8.1. Expansion and Acquisition Analysis8.1.1. Expansion8.1.2. Acquisitions8.2. Partnerships/Collaborations/Agreements/Exhibitions9. Company Profiles9.1. Company Overview9.2. Financial Performance9.3. Product/Services Benchmarking9.4. Recent Developments MedisafeForward HealthAllmJohnson & JohnsonPulsaraHospifyTigerConnectVocera CommunicationsTwiagePatientSafe SolutionsImprivataVoalteAlayacareSiiloPivot Design GroupArgusoft For more information about this report visit https://www.researchandmarkets.com/r/zdom91 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The current S&P 500 index dividend yield is a measly 1.47%. That's pretty skimpy if you rely on dividend income. Fortunately, you can do a lot better than 1.47%. Here are three dividend stocks that are an income investor's dream.
The "Facility Management Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed above 114 million on Monday, according to data aggregated by Johns Hopkins University, while the death toll rose above 2.53 million. The U.S. has the highest case tally in the world at 28.6 million and the highest death toll at 513,092. The U.S. added 50,925 new cases on Sunday, according to a New York Times tracker, and at least 1,129 people died. The U.S. has averaged 67,868 cases a day in the past week, down 26% from two weeks ago. The U.S. Food and Drug Administration on Saturday granted emergency authorization to the vaccine developed by Johnson & Johnson, that has the advantage of being a one-dose regimen that does not require the refrigeration required by the existing vaccines. The move has bolstered hopes that vaccination can now speed up. Brazil has the second highest death toll at 254,942 and is third by cases at 10.6 million. India is second worldwide in cases with 11.1 million, and now fourth in deaths at 157,157. Mexico has the third highest death toll at 185,715 and 13th highest case tally at 2.1 million. The U.K. has 4.2 million cases and 123,083 deaths, the highest in Europe and fifth highest in the world.
METTAWA, Ill., March 01, 2021 (GLOBE NEWSWIRE) -- Brunswick Corporation (NYSE: BC) continues to build on its ACES (Autonomy, Connectivity, Electrification & Shared Access) strategy to develop solutions to further improve boater experiences by advancing the efficiency and capabilities of its core product lines. In support of this effort, the Company has announced that Jason Arbuckle has been promoted to a newly formed role of Marine Autonomy Technology Lead. This new strategic position will enable the Enterprise to lead the delivery of highly automated-to-autonomous solutions for the recreational marine industry. Brunswick continues to identify and establish new leaders with strong technology experience to strengthen its capabilities in autonomy, connectivity, and electrification. In November, Brunswick announced the hiring of John Oenick as Director, Enterprise Electrification, a role that has allowed Brunswick to support and deliver electrification solutions across the Company. “Automation and control technologies are rapidly emerging critical enablers for delivering innovation through smart-connected recreational marine products and experiences,” said Dave Foulkes, Brunswick Corporation CEO. “Jason is a proven leader who will help us advance our capabilities, providing leadership to our emerging autonomy teams across the entire enterprise.” “I am excited for this opportunity to lead advancements in Marine Autonomy for Brunswick Corporation,” said Arbuckle. “Brunswick has made advancements in vessel control over the last several years through assisted docking, joystick piloting, Skyhook and more, and I believe autonomous and driver assistance features are the next steps in enabling an easier boating experience. I look forward to working with all the Brunswick divisions on enhancing marine autonomy.” Arbuckle joined Mercury Marine in 1997 and has since advanced through the company, working to lead some of the company’s many award-winning innovative technology solutions. Throughout his career, Arbuckle has been instrumental in the development of helm software for Mercury Marine products from single engine to six engine vessels and has been granted more than 45 patents related to marine control systems. Most notably, he led Mercury’s Vessel Control Team to develop AutoPilot systems, SkyHook, BowHook and DriftHook, as well as the vessel control software efforts for Starfish 1 and 2. Jason has a BS, MS and Ph.D. in Electrical Engineering from Michigan Technological University and contributes his time and talent to students entering the field at the Naval Post Graduate School, the US Navy, MIT providing guidance on their Philos autonomous vessel, as well as, student SAE projects at UW Madison. About Brunswick: Headquartered in Mettawa, Ill., Brunswick Corporation’s leading consumer brands include Mercury Marine outboard engines; Mercury MerCruiser sterndrive and inboard packages; Mercury global parts and accessories including propellers and SmartCraft electronics; Power Products Integrated Solutions; MotorGuide trolling motors; Attwood, Mastervolt, and Whale marine parts; Land ’N’ Sea, BLA, Payne’s Marine, Kellogg Marine, and Lankhorst Taselaar marine parts distribution; Mercury and Quicksilver parts and oils; Bayliner, Boston Whaler, Crestliner, Cypress Cay, Harris, Heyday, Lowe, Lund, Princecraft, Quicksilver, Rayglass, Sea Ray, Thunder Jet and Uttern boats; Boating Services Network, Freedom Boat Club and Boat Class. For more information, visit brunswick.com. CONTACT: Lee Gordon Vice President – Brunswick Global Communications & Public Relations Brunswick Office: 847-735-4003 Mercury Office: 920-924-1808 Cell: 904-860-8848 Lee.Gordon@Brunswick.com
Rocket Lab today unveiled plans for its Neutron rocket, an advanced 8-ton payload class launch vehicle tailored for mega-constellation deployment, interplanetary missions and human spaceflight.
Six cases involving the Brazil variant of coronavirus have been detected in the UK.
U.K. home builders surged on Monday, on reports the government is set to introduce a program that would guarantee mortgages with deposits as low as 5%.
Electric vehicles are all the rage, in particular among public officials who do not have to face voters. Not so much among consumers, who know their individual needs and strive to make purchase decisions that satisfy them. These realities explain why the proponents of policies forcing ever more EVs upon the market prefer to implement such requirements in ways insulated from democratic accountability. That is an accurate summary of the current political campaign in Minnesota to expand by regulatory fiat the market for EVs, by requiring that auto dealers in the state sell a certain number of them or face a penalty, moving the state toward California’s “zero emissions” automotive standard. The proposed mandate would engender massive dislocation and increased costs in the state’s transportation and agricultural sectors, adverse effects that would be borne by virtually every resident in the state. It would also create a series of large and adverse environmental impacts that the proponents of this change prefer not to discuss. Finally, it is easy to suspect that one key objective behind the mandate is to force a shift of population and economic activity away from rural, exurban, and suburban regions in the state toward urban areas, thus creating a massive transfer of wealth from residents, business owners, and workers in the former regions toward those in the latter. The usual climate “crisis” justification for the EV mandate does not withstand scrutiny: Minnesota greenhouse gas (GHG) emissions account for 1.7 percent of the U.S. total (Table 2). Net-zero emissions by the entire U.S. would reduce global temperatures by 0.1 degrees by 2100, using the Environmental Protection Agency climate model under assumptions consistent with the modern peer-reviewed literature on the temperature effects of reduced GHG emissions. (The entire Paris agreement: 0.17 degrees.) Elimination of all Minnesota GHG emissions would reduce temperatures by about 17 ten-thousands of a degree. Elimination of all Minnesota GHG emissions from the transportation sector (about 35 percent of the total) would reduce global temperatures in 2100 by about 6 ten-thousandths of a degree. How large are the costs that the state’s residents ought to bear to achieve such laughable outcomes? Those costs would be enormous. The proposed artificial increase in the market share of EVs will require indirect subsidies in the form of higher prices for conventional vehicles, with part of those sales revenues used to reduce the prices of the EVs. That is why a regulatory requirement is necessary: EVs cannot satisfy consumer needs and preferences. Minnesotans should prepare to pay thousands of dollars more for conventional autos and trucks. Meanwhile, EVs cost an average of around $20,000 more than their conventional counterparts. And if the pricing distortions collapse the market for conventional vehicles or fail to yield the EV market share demanded by the regulators, the only available remedy will be direct subsidies financed by the taxpayers. EVs have poor range, particularly in cold climates, long charging times, and other major disadvantages. Such vehicles are not viable for the agricultural sector, for people with lengthy commutes, and for many others who would be forced to pay higher prices for conventional vehicles to subsidize EV purchases by urban residents. And do not let the “zero emissions” label fool you: EVs create their own set of massive environmental problems, among which are the emissions from producing these vehicles and from the power generation needed to charge their batteries. (A power system based mostly on wind and solar power cannot work, simply as a matter of electrical engineering.) There is also the “rare earth” and other toxic metal pollution attendant upon the production of the batteries, the massive disposal problem for the batteries at the end of their useful lives, and on and on. EVs are anything but “clean.” The EV mandate, by making personal and business transportation much more costly and difficult, would, as noted above, create over time a household and business location shift away from rural, exurban, and suburban regions toward urban centers. More fundamentally, it would serve the broader leftist goal of making massive numbers of ordinary people ever more dependent on government, by making personal transportation vastly more difficult. California in 2006 became the first state to adopt “climate” policies; the prevailing slogan was “California has to be a leader!” It is no accident that prices for electric power in California now are the fifth-highest in the lower 48 states, an outcome that has imposed real economic suffering upon the poorer residents of the hotter inland regions. The California EV mandate is creating similar adverse effects that are beginning to emerge. And now in Minnesota, various bureaucrats, “experts,” and politicians propose to emulate the California “zero-emissions vehicles” requirement in the Star of the North state. Is there a reason that Minnesota has to be a follower?
My boss advised against getting a dog. And it should be said that my dog has annoyed my boss, although canine behavior wasn’t the basis of his advice. Since the pandemic pushed our recording sessions fully remote, listeners to The Editors podcast at National Review have heard stray barks, or — and I apologize for this — they heard her panting over my brilliant analysis of the latest Trump tweet. You see, I had forgotten to pull the blinds down, and she saw a squirrel in a nearby tree, and, well, I had to calm her down. But the show must go on, right? My dog is named Dolly. She is a Kerry blue terrier and just turned one. Two things changed as the pandemic started. The first is that we moved our family of two adults and three young children out of a small (but beloved) two-bedroom apartment and into a single-family home with a yard. This was less than a month before the great lockdowns began. That was extraordinary good luck. A few weeks later, when the outside world closed down and we’d lost our schools and babysitter, we had a puppy. That was impulsive. My wife just suggested it, while the kids were in the bath one night. The world was going to shut down. I had pulled my daughter out of school, and then school was shut down a few days later. I wouldn’t be traveling to the office, and we would need something fun to occupy our time. We probably wouldn’t be traveling overseas anytime soon. There was literally no more convenient time to train a dog. And maybe there’d be more dogs available because people were changing plans. Just as in real estate, we found there were a few weeks of demand crash and stasis in the dog market, followed immediately by a surging demand that far outstripped supply. After a few messages on different Facebook groups, we were the first people on our street with a pandemic dog. Not the last. Goldendoodles, poodle mixes, and the shelter dogs that are always advertised as “Schnauzer mixes” all made their debut in the months afterward. My agent — formerly a Brooklyn guy, who moved into the suburbs — reported that his dog was losing weight during COVID. Such were the walks. The dog itself was my wife’s concession to me. The name was mine to her. We drew up lists and mine was filled with the likes of Rosín (Ro-sheen), and Méabh (Maeve). Of course, it was a Kerry blue, with all the blarney legends about Ireland’s wild west coast attached to her breed. The Irish nationalist Michael Collins gave his Kerry blue his own prison name, Convict 224. Daniel Tenreiro would say that’s “based,” but imitating Collins now would be “cringe.” Somewhere on my list, I wrote “Dolly.” And that’s what my wife picked. Let’s get the bad stuff out of the way. Dolly needs to be outside four times a day not to ruin our floors. She has figured this out and does her best to accommodate our timing. We haven’t gotten around to building a fence in the backyard, so we need to go out with her. We thought that our house was far back enough from the street that Dolly would not, like the other dogs, bark her head off when dogs pass our property. This was wrong. And besides, there’s no way to pull a house far enough away from the squirrels. Also, at some point, Dolly transferred her primary affection away from me and to my wife — probably because I walk her, but my wife feeds her. Also, the room my wife claimed for her own home office and craft room has a better view of the squirrels. For a few months there, the toddlers could not stop chasing Dolly around the living room, and there was some nipping. Around month four, we were exhausted from the pandemic and addled by social isolation and “Zoom school.” Dolly would launch herself at any running child. The children would fall and scream like they had been shot. The bearded black bullet had felled them again. Sharp words like “regret” and “mistake” were uttered. But there are no scars and no blood drawn. A few months later, Dolly learned not to nip. Then she mostly learned not to knock them down. She is a goofball with them, and the worst thing she wants to do to the children is steal their toast. It’s weird how much she loves toast! Then again, we butter it with Kerrygold. Dolly is just 27 pounds, and maybe 18 inches at the withers. And when wet, she looks spindly and fragile. But her fur and beard give her a more imposing look. She has the bark and growl of a much larger dog. When she barks near the front of our house, you can hear our doorbell reverberating from it. She’s still a jet-black bullet. And I found that I’m glad for it. As with a lot of people, the past year has made me a little more sensitive to threats that aren’t the coronavirus. The political temperature has been building for years, and the number of hate-mailers and anonymous trolls who really do prove to you that they are stalking you online keeps increasing. I thought about investing a significant chunk of my yearly income in a trained “protection dog” at one point. But Dolly might be enough to fill the “dog layer” of home security. She has a nose for good order. Just one example. She’s gotten used to the idea that at night, she and I are the last ones in. After we take our late-night walk, the front door shuts for good. But this weekend, I remembered just before I fell asleep that I needed to recharge my flashlight, and it was sitting in my coat in our front vestibule. Dolly was on the couch watching the Great British Baking thing with my wife. But when I opened the front door, I heard her leap, and she put on her full doorbell-rattling “big dog” bark, bounding toward the front door. She was a terror. This is the best alarm system money can buy. As she rounded the corner, she realized it was me and gave me an offended look as if to say, “Why are you up and out here?” The tail wagged quizzically, and then she settled and went back to the couch. That’s our black bullet. The times that she has snapped a lead during a squirrel chase, or that a leash has slipped out of hand while navigating the ice, she tears away. She runs the way a gold-medal Olympic ice skater leaps — with an impossible combination of speed and balletic elegance. It’s a genuinely beautiful and intimidating display. Our worry about how to “get her back” is completely cut through by our smiling admiration in watching her go and go. Eventually we find a piece of dried meat stinky enough to get her back in hand. And actually, that’s her best value in these times: the simplicity of her needs and instincts. Dogs chase squirrels, they seek tasty food, they frighten evildoers, and at the end of the day, they lay next to the humans they love. Humans can, for a short time, refuse to tend to their needs — for fresh air, sun and feasts, or for recreation, affection, and rest. And in the pandemic, it has been tempting to ignore those physical and mental-health needs. It’s too dangerous to play, or venture, or fight. And damnit, there’s too much important stuff happening on the Internet to rest. But Dolly has been there to remind us what we are. The icons and the crucifixes in our home call us to attend to the supernatural realities, and our needs for grace, prayer, and contemplation. But Dolly is Nature’s 27-pound icon. She makes it impossible to ignore her needs — and therefore impossible to discount our own. Five stars. Would recommend.
As President Biden begins his engagement with our closest allies and partners in the Middle East, there is an opportunity to build on the momentum of the Abraham Accords to advance U.S. interests and leverage the emerging bonds among our closest regional partners. American leadership was a necessary (though by itself insufficient) condition to the normalization of relations between Israel and the United Arab Emirates (UAE), and will remain essential to building cooperative relationships between Israel and other formerly hostile powers. Biden should expand on this inheritance from the Trump administration, not try to move beyond it. The alignment of our regional partners and allies in both the economic and security domains will ensure that the legacy of the Accords incentivizes other states to normalize relations with Israel and forge new economic and security partnerships to meet the myriad challenges posed not only by Iran, but also by the malign influence of China and Russia. Following the announcement of diplomatic normalization between Israel and the UAE in August of last year, Bahrain, Sudan, and Morocco quickly followed suit. What motivated this move? Certainly, the threat from violent extremism and Iran animated the members, but so too did the promise of cooperation and recovery from the pandemic’s impact on their economies. How can the U.S. capitalize on this momentum to persuade other countries to join and expand the Accords? The first step is to establish trust. This begins with cooperation on security threats that preoccupy the region’s leaders. In addition to restating joint commitments to counter violent extremism, we should ensure close collaboration to address the regional threat from Iran and its surrogates. The State Department can rapidly affirm the interagency review that approved of arms sales providing our regional partners with the tools required to combat shared threats, recognizing that both Russia and China would be happy to fill the void without restrictions. Next, we should expand scale. Discussions should be advanced incrementally and can include the commencement of international flights, the opening of commercial offices, and reducing trade restrictions. It can also include establishing representation for the Accords’ members not already in the Gulf Cooperation Council to provide a multilateral forum for collaboration. Recognizing the steps taken by Egypt in 1979 and Jordan in 1994 warrants their inclusion and a corresponding review of our security cooperation to ensure we remain their preferred partner. We must also expand scope. The initial focus on economic, cultural, and social issues was intentional, but was always to meant to expand and address the complex security issues faced by its members, including the regional threats from Iran, violent extremism, and Chinese and Russian malign influence. In this context, the foundational work to establish a regional security architecture to share the burdens and make effective use of the region’s capabilities warrants consideration. This would increase interoperability, expand compliance with international law through integration of forces and the principles to which they adhere, and reduce the commitment of U.S. resources. Perhaps most important, it would serve to constrain and reverse the concerted efforts of China and Russia to expand their influence over a region that has the potential to afford them both clients for strategic-weapon sales and the corresponding relationships that undermine our interests. Finally, the U.S. should lead efforts to institutionalize. Moving beyond the current cluster of bilateral or trilateral arrangements, the U.S. should help establish a secretariat among the Accords’ members (including Egypt and Jordan) to accelerate developments, provide a forum to expand membership, and organize these activities under a single umbrella. Conducting bilateral discussions can be complicated but can be pursued more effectively in some instances within a multilateral forum. The U.S. can consider appointing a special envoy to elevate the profile of the secretariat and signal its importance to existing and future members. This mechanism should continue to align strategic investment tools such as the U.S. International Development Finance Corporation (DFC) and Export-Import Bank (EXIM), which both played critical roles in securing and implementing the Accords. Without U.S. leadership, the historic agreements would not have been concluded; absent sustained investment, they will fail to achieve their potential. This would constrain the region’s economic recovery from the pandemic, undermine any negotiation with Iran, erode support for counterterrorism cooperation, open a door to Russian and Chinese malign influence, compromise regional stability, discourage essential cooperation, and provide an opportunity for ISIS’s and al-Qaeda’s resurgence. Naturally, the inverse holds if we seize the opportunity that the region’s historic transformation offers. We could build upon it to enhance regional stability, security, and trade and the opportunity of a U.S.-led regional security architecture built to safeguard an economic foundation that will endure, reducing our costs while constraining our adversaries. The Abraham Accords constitute the beginning of a regional evolution requiring American leadership to ensure its growth and development. The alignment of our regional partners and allies in both the economic and security domains constrains Iran, but equally important, it limits the malign influence of China and Russia, both of which oppose us and neither of which recognizes Israel’s Qualitative Military Edge (the principle that Israel must have more and better weapons than its neighbors). They will also continue to manufacture and exploit fissures among the U.S. and its regional partners if we fail to seize this historic opportunity in the region to advance America’s interests with significantly fewer resources and more capable partners, integrated like never before. Though he’s unlikely to admit it, Biden received something of a gift from the Trump administration with the Accords. What comes next is up to him.
Congress isn’t even waiting to lift the decade-long moratorium on earmarking before starting to pig out. Look no further than the $1.9 trillion bill being touted by Democrats as the latest response to the COVID pandemic — a proposal that’s being fast-tracked through both chambers. Tucked within its nearly 600 pages are a number of pet projects — also known as “earmarks” — that have absolutely nothing to do with COVID. Take, for example, the $1.5 million set aside for a bridge connecting New York and Canada. Elsewhere you will find a cleverly worded provision that earmarks $140 million for a subway from San Francisco to Silicon Valley. These projects will benefit the Democratic leaders of the Senate and House. This is precisely how earmarking works. Secret spending is dropped into a “must-pass” bill at the behest of powerful politicians and is typically totally unrelated to the merits of the project or the purpose of the legislation. House Appropriations Committee chair Rosa DeLauro (D., Conn.) and Senate Appropriations Committee chairman Patrick Leahy (D., Vt.) claim that earmarks will be restored with more transparency and limitations on where the money can be directed. But putting lipstick on earmarks does not prevent them from being good old-fashioned pork-barrel spending and the most corrupt, costly, and inequitable practice in the history of Congress. Earmarking — by design — will never be transparent. Unlike the federal grant-making process, there is no standard for competition for the grants, and taxpayers have no ability to examine how the money was doled out. Earmarking is quite literally decided in secret. More insidiously, decisions about who gets earmarks and who doesn’t are usually treated as a form of political reward for the well-connected or as punishment for those who don’t follow the party line. Convicted super lobbyist Jack Abramoff affectionately referred to it as the congressional “favor factory.” It should come as no surprise, then, that the return of earmarks has been most celebrated by Washington lobbyists who know the practice will be a boon to their business. Supporters of earmarks — a.k.a., “earmarxists” — argue that they represent a small amount of money. According to Citizens Against Government Waste’s (CAGW) Congressional Pig Book, the most spent on earmarks in one year was $29 billion, which represented 1 percent of total discretionary spending. Only in Washington, D.C., would someone try to convince you with a straight face that $29 billion is a small amount of money. This diverts from the true reason that members of Congress want to restore earmarks: power and control. Frankly, Congress does not need any new incentives to spend money given the total spent in response to the COVID-19 pandemic could soon reach more than $5.7 trillion. Yes, you read that correctly. And the latest bill was passed by the House even though $1 trillion of the prior relief funds has not yet been spent. The earmarks process is also inherently inequitable. When members of Congress were required to add their names to the earmarks they received, taxpayers were able to see that the 81 members of the House and Senate appropriations committees received 51 percent of the money and 61 percent of the earmarks. CAGW’s earmark database contains 111,114 earmarks that have cost taxpayers $375.7 billion since the first Pig Book was released. A few of them merit special recognition, including $3.8 million to conserve Old Tiger Stadium in Detroit, Mich.; $1 million for a Woodstock museum in Bethel, N.Y.; $500,000 for a teapot museum in Sparta, N.C.; and $273,000 to study Goth culture in Blue Springs, Mo. And, perhaps the most infamous earmark of all: the Bridge to Nowhere in Alaska. What’s even worse? None of these pricey pet projects were even completed. There’s good reason why earmarks are referred to as pork: They stink, and they’re messy. With the national debt headed toward $30 trillion, the last thing Congress needs to be focused on is finding other ways to waste money. Joni Ernst is a Republican senator from Iowa, and Tom Schatz is the president of Citizens Against Government Waste.
In the final weeks of Trump’s presidency, his administration issued several “midnight regulations,” including a new rule from the Environmental Protection Agency (EPA) tightening the clearance levels for the amount of lead allowed to remain in dust on floors and windowsills in buildings after certain lead-based paint activities. While it seems reasonable, the new rule imposes costs on owners of older residential properties beyond what is necessary to meet the EPA’s dust-lead hazard standard, adding to pressures to replace older low-cost housing. It should be reconsidered. (Disclosure: The author owns two older homes, of which one is a rental property.) The EPA’s new rule cuts the levels of dust lead that are permissible on floors and on windowsills following abatement activities by 60 percent. Individual surfaces found to have dust-lead levels at or above the new clearance levels must be recleaned, resampled, and subjected to retesting. Two distinct issues arise with these new standards. First, they are more stringent than necessary to ensure that homeowners comply with the EPA’s already-tightened 2019 dust-lead hazard standards (DLHS). The 2019 regulation defines hazards to be present if the weighted average levels of lead for all surface samples of floors or interior windowsills exceed specific thresholds. Under the EPA midnight regulation, if average dust-lead levels are below those thresholds, but specific individual surfaces exceed it, then each such surface must be recleaned, resampled, and subjected to additional testing. This surface-by-surface approach to dust-lead clearance is not new. But the EPA’s newly stringent clearance standards make it more problematic by requiring recleaning, resampling, and retesting of housing that otherwise complies with the EPA’s lead hazard standard. Second, the EPA’s rule allows no tradeoffs between dust-lead levels on floors and windowsills in a given home. For example, if the average windowsill dust-lead level were dramatically below the threshold, could the dust-lead level on the floor be a tad above the cap? Not under EPA regulations. This scenario would require additional cleaning, sample collection, and testing under the new clearance standards. But the risks of elevated blood lead would be lower than if average dust-lead levels were right at the maximum levels. The EPA’s earlier actions, such as its 2019 dust-lead hazard rule, also neglected to recognize such tradeoffs. Failure to recognize them is problematic now, however, because the latest dust-lead clearance regulation implements the dust hazard regulation and is intended to demonstrate that attaining the clearance standards assures compliance with dust-lead hazard standards. These are not petty issues. The additional cleanup and testing of individual surfaces is costly, about $262 for single-family homes. The full costs also include possible delays in occupancy while surfaces are retested. The EPA estimates that nearly 7 percent of the housing subject to clearance standards under the new rule will have to go through a second dust-lead check. The total impact of the EPA’s rule may include indirect effects from the incorporation of the new standards into other federal programs. The Department of Housing and Urban Development (HUD), for example, has standards for clearance of residential housing and child-occupied facilities that it supports. But those standards state that “clearance examinations following abatement of lead-based paint or lead-based paint hazards shall be performed in accordance with [EPA regulations]” that include the EPA’s newly issued dust-lead clearance standards. EPA’s surface-by-surface approach, which neglects tradeoffs between lead on floors and lead on windowsills, is echoed in the programs of different states, some of which have requirements more stringent than the EPA’s in various respects. Maryland requires collection and testing of multiple dust-lead samples as a condition of occupancy of older housing units by new tenants or owners. Massachusetts requires such inspections for lead in rental homes where children under six are present. New York City has dust-lead clearance levels for re-occupancy that are more stringent than those of the EPA — 50 percent lower for interior window sills — but also follows the EPA’s surface-by-surface approach to clearance. This EPA action illustrates the importance of scrutinizing “midnight regulations” and highlights the need for review of existing regulations by the incoming Biden administration. The Congressional Review Act offers a fast-track procedure for Congress to overturn new regulations, but it is difficult to imagine this Congress overturning an overzealous regulation. For this rule, however, Congress and the Biden administration might well ask whether it should not be modified or delayed until the EPA can identify a truly cost-effective and risk-based approach that avoids putting an additional regulatory burden on property owners beyond that required by the EPA’s 2019 DLHS.
Rocket Lab USA, Inc. ("Rocket Lab" or "the Company"), a global leader in launch and space systems, and Vector Acquisition Corporation (Nasdaq: VACQ) ("Vector"), a special purpose acquisition company backed by leading technology investor Vector Capital, announced today that they have entered into a definitive merger agreement that will result in Rocket Lab becoming a publicly traded company. The transaction is estimated to be completed in Q2 2021 and, at that time, Vector will change its name to Rocket Lab USA, Inc. and the combined company will trade under the Nasdaq ticker symbol RKLB.
REI Announces Timing of Its Fourth Quarter and Full Year 2020 Earning Release and Conference Call
PQ Group Holdings Accelerates Transformation: Enters Agreement to Sell Performance Chemicals Business and Acquires Niche Catalyst Activation Business
PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease (“CKD”) caused by Alport syndrome to the U.S. Food and Drug Administration (“FDA”). This NDA submission is based on the efficacy and safety data from the CARDINAL Phase 3 clinical trial. The submission includes a request for Priority Review, which, if granted, would shorten the FDA’s review of the NDA to eight months from the time of submission, versus a standard review timeline of 12 months. If approved, bardoxolone would become the first therapy specifically indicated for the treatment of CKD caused by Alport syndrome. “This NDA submission marks an important step toward making a treatment available for patients with Alport syndrome, a serious, progressive disease with an urgent need for new therapeutic options,” said Warren Huff, Reata’s President and Chief Executive Officer. “I want to thank all those who made this moment possible, especially Alport syndrome patients and their families. We look forward to next steps on the path to making bardoxolone available as a first-in-class therapy for Alport syndrome, pending NDA acceptance, review, and drug approval." About Alport Syndrome Alport syndrome is a rare, genetic form of CKD caused by mutations in the genes encoding type IV collagen, which is a major structural component of the glomerular basement membrane in the kidney. The kidneys of patients with Alport syndrome progressively lose the capacity to filter waste products out of the blood, which can lead to end-stage kidney disease and the need for chronic dialysis treatment or a kidney transplant. Alport syndrome affects both children and adults. In patients with the most severe forms of the disease, approximately 50% progress to dialysis by age 25, 90% by age 40, and nearly 100% by age 60. According to the Alport Syndrome Foundation, Alport syndrome affects approximately 30,000 to 60,000 people in the United States. There are currently no approved therapies to treat CKD caused by Alport syndrome. About the CARDINAL Clinical Study CARDINAL was an international, multi-center, Phase 2/3 study that enrolled patients from 12 to 60 years old with a confirmed genetic or histological diagnosis of Alport syndrome, baseline estimated glomerular filtration rate (“eGFR”) values between 30 to 90 mL/min/1.73 m2, and on stable renin-angiotensin-aldosterone system blockade unless contraindicated. The Phase 3 portion of CARDINAL was a double-blind, placebo-controlled, randomized trial that enrolled 157 patients with CKD caused by Alport syndrome at approximately 50 study sites in the United States, Europe, Japan, and Australia. Patients were randomized 1:1 to once-daily, oral bardoxolone or placebo. The primary endpoint for Year 2 of the study was the change from baseline in eGFR after 100 weeks of treatment. The key secondary endpoint for Year 2 of the study was the change from baseline in eGFR at Week 104 (four weeks after last dose in second year of treatment). Results from CARDINAL demonstrated that patients treated with bardoxolone experienced a statistically significant improvement in kidney function as measured by eGFR at Week 100 and Week 104, compared to patients treated with placebo. Bardoxolone was generally reported to be well tolerated in this study, and the safety profile was similar to that observed in prior trials. The reported adverse events (“AE”) were generally mild to moderate in intensity, and the most common AEs observed more frequently in patients treated with bardoxolone compared to patients treated with placebo were muscle spasms and increases in aminotransferases. About Bardoxolone Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome. In addition to the CARDINAL Phase 3 study, bardoxolone is currently being studied in FALCON, a Phase 3 study for the treatment of ADPKD, MERLIN, a Phase 2 study for the treatment of patients with CKD at risk of rapid progression, and AYAME, a Phase 3 study for the treatment of diabetic kidney disease that is being conducted by our licensee, Kyowa Kirin Co., Ltd., in Japan. Bardoxolone treatment has produced positive results in Phase 2 studies in patients with CKD caused by ADPKD, IgA nephropathy, focal segmental glomerulosclerosis, and type 1 diabetes. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency. Contact: Reata Pharmaceuticals, Inc. (972) 865-2219 https://www.reatapharma.com/contact-us/ Investor Relations & Media: Manmeet Soni (469) 299-9130Andres Lorente (469) firstname.lastname@example.org email@example.com https://www.reatapharma.com/ Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including the detailed factors discussed under the caption “Risk Factors.” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.